Product Code: GVR-4-68040-007-6
HLA Typing Market Growth & Trends:
The global HLA typing market size is expected to reach USD 1.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.7% from 2023 to 2030. The increasing stem cell transplantation coupled with expanding the use of human leukocyte antigen (HLA) typing in other applications is expected to support the growth of the market. From 2016 to 2020, around 111,984 hematopoietic cell transplantations were performed in the U.S. Out of those, 89% of cell sources were peripheral blood, 9% were from bone marrow and 2% were from cord blood. Similarly, there are over 219 centers in the region for performing hematopoietic cell transplantations.
HLA typing is expected to be a valuable source of information for various basic and translational research studies. Since some HLA alleles can impact the severity and susceptibility of infectious diseases, while other HLA alleles are related to the diverse predispositions of genetics to diseases such as autoimmune conditions and cancer. Gaining insights into which haplotypes can have a higher probability of critical disease or poor prognosis can be specifically useful in translational applications for developing therapeutics. Hence, HLA typing usage in research applications is expected to have a considerable contribution to the overall market estimates.
The COVID-19 pandemic adversely impacted the market. Although there was a handful of researchers with the concept of integrating HLA typing with COVID-19 testing. For instance, in August 2021, the scientific evidence from research published in the European Journal of Medical Research suggested including HLA tying in clinical trials and combining it with the COVID-19 test to increase the speed of identifying a predictor in the population.
The growing strategic initiatives by the companies are anticipated to boost market growth. For instance, in March 2022, Immucor, Inc. announced to launch a HLA typing software as a supporting product for its HLA typing assay. The software is expected to ease and quicker the NGS analysis process with a cost-saving option for the users.
On the other hand, the increasing number of recipients removed from the waiting list for organ transplantation is likely to affect the usage of HLA typing. The reasons for the removal from the list are deterioration in the patient's condition, patient's death, or recovery from the disease. For instance, from January 2021 to December 2021, 6 patients from Barnes-Jewish Hospital died due to the shortage of organs, while 11 patients' conditions deteriorated.
HLA Typing Market Report Highlights:
- By product, the reagents consumables segment is projected to establish the fastest growth rate over the forecast period. Since increasing product development by the existing players to expand the usage of HLA typing in various fields of research, such as immunotherapies
- By application, the diagnosis segment is anticipated to have the fastest growth rate with a larger share in 2022. Owing to the increase in organ transplantations and showcasing evidence of being an important source of information for infectious diseases, hence, propelling market growth
- By technique, the sequenced-based molecular assay segment is anticipated to have the fastest CAGR between 2023 to 2030. Since, it has the ability to generate clear, phase-resolved HLA typing with a single assay
- By end-user, the hospitals and transplant centers segment is projected to have a majority of the market share in 2022. This is attributed to the presence of well-equipped facilities for research in developed countries
- North America has strengthened its regional position in the market with 46.94% of the overall market share. This is attributed to the presence of transplant centers and clinics, along with the existence of key players in the region
Table of Contents
Chapter 1 Research Methodology
- 1.1 Country Wise Market: Base Estimates
- 1.2 Global Market: CAGR Calculation
- 1.3 Region-Based Segment Share Calculation
- 1.4 Research Scope & Assumptions
- 1.5 List of Data Sources
- 1.5.1 Data for primary interviews, by sources
- 1.5.2 Data for primary interviews, by region
Chapter 2 Executive Summary
Chapter 3 HLA typing Market Variables, Trends & Scope
- 3.1 Market Segmentation & Scope
- 3.2 Market Driver Analysis
- 3.2.1 Increasing number of organs transplants
- 3.2.2 Technology advancement in testing techniques
- 3.2.3 Adoption of HLA testing in Pharmacogenetic
- 3.3 Market Restraint Analysis
- 3.3.1 Stringent Regulatory Framework
- 3.4 HLA typing - SWOT Analysis, By Factor (political & legal, economic, and technological)
- 3.5 Industry Analysis - Porter's
- 3.6 HLA Typing Market: Market Position Analysis, 2022
- 3.7 COVID-19 Impact Analysis
Chapter 4 HLA Typing Market: Product Estimates & Trend Analysis
- 4.1 HLA Typing Market: Product Movement Analysis
- 4.2 Instruments
- 4.3 Reagents & consumables
- 4.3.1 Reagents & consumables market
- 4.4 Software & Services
- 4.4.1 Software & services market
Chapter 5 HLA Typing Market: Application Estimates & Trend Analysis
- 5.1 HLA Typing Market: Application Movement Analysis
- 5.2 Diagnosis
- 5.3 Research
Chapter 6 HLA Typing Market: Technique Estimates & Trend Analysis
- 6.1 HLA Typing Market: Technique Movement Analysis
- 6.2 Molecular Assay
- 6.2.1 Molecular assay market
- 6.3 Sequenced-based Molecular Assay
- 6.3.1 Sequenced-based molecular assay market
- 6.4 Non-Molecular Assay
- 6.4.1 Non-molecular assay Market
Chapter 7 HLA Typing Market: End-user Estimates & Trend Analysis
- 7.1 HLA Typing Market: End-user Movement Analysis
- 7.2 Commercial Service Providers
- 7.2.1 Commercial service providers market
- 7.3 Hospitals and Transplant Centers
- 7.3.1 Hospitals and transplant centers market
- 7.4 Research Labs & Academic Institutes
- 7.4.1 Research labs & academic institutes market
Chapter 8 HLA typing Market: Regional Estimates & Trend Analysis, by Product, Application, Technique, End-use
- 8.1 HLA typing Market Share By Region, 2022 & 2030
- 8.2 North America
- 8.2.1 SWOT Analysis
- 8.2.1.1 North America HLA typing market, by product
- 8.2.1.2 North America HLA typing market, by application
- 8.2.1.3 North America HLA typing market, by End-user
- 8.2.1.4 North America HLA typing market, by technique
- 8.2.2 U.S.
- 8.2.2.1 Key Country Dynamics
- 8.2.2.2 Target Disease Prevalence
- 8.2.2.3 Competitive Scenario
- 8.2.2.4 Regulatory Framework
- 8.2.2.5 Reimbursement Scenario
- 8.2.2.6 U.S. HLA typing market, by product
- 8.2.2.7 U.S. HLA typing market, by application
- 8.2.2.8 U.S. HLA typing market, by End-user
- 8.2.2.9 U.S. HLA typing market, by technique
- 8.2.3 Canada
- 8.2.3.1 Key Country Dynamics
- 8.2.3.2 Target Disease Prevalence
- 8.2.3.3 Competitive Scenario
- 8.2.3.4 Regulatory Framework
- 8.2.3.5 Reimbursement Scenario
- 8.2.3.6 Canada HLA typing market, by product
- 8.2.3.7 Canada HLA typing market, by application
- 8.2.3.8 Canada HLA typing market, by End-user
- 8.2.3.9 Canada HLA typing market, by technique
- 8.3 Europe
- 8.3.1 SWOT Analysis
- 8.3.1.1 Europe HLA typing market, by product
- 8.3.1.2 Europe HLA typing market, by application
- 8.3.1.3 Europe HLA typing market, by End-user
- 8.3.1.4 Europe HLA typing market, by technique
- 8.3.2 Germany
- 8.3.2.1 Key Country Dynamics
- 8.3.2.2 Target Disease Prevalence
- 8.3.2.3 Competitive Scenario
- 8.3.2.4 Regulatory Framework
- 8.3.2.5 Reimbursement Scenario
- 8.3.2.6 Germany HLA typing market, by product
- 8.3.2.7 Germany HLA typing market, by application
- 8.3.2.8 Germany HLA typing market, by End-user
- 8.3.2.9 Germany HLA typing market, by technique
- 8.3.3 UK
- 8.3.3.1 Key Country Dynamics
- 8.3.3.2 Target Disease Prevalence
- 8.3.3.3 Competitive Scenario
- 8.3.3.4 Regulatory Framework
- 8.3.3.5 Reimbursement Scenario
- 8.3.3.6 UK HLA typing market, by product
- 8.3.3.7 UK HLA typing market, by application
- 8.3.3.8 UK HLA typing market, by End-user
- 8.3.3.9 UK HLA typing market, by technique
- 8.3.4 France
- 8.3.4.1 Key Country Dynamics
- 8.3.4.2 Target Disease Prevalence
- 8.3.4.3 Competitive Scenario
- 8.3.4.4 Regulatory Framework
- 8.3.4.5 Reimbursement Scenario
- 8.3.4.6 France HLA typing market, by product
- 8.3.4.7 France HLA typing market, by application
- 8.3.4.8 France HLA typing market, by End-user
- 8.3.4.9 France HLA typing market, by technique
- 8.3.5 Italy
- 8.3.5.1 Key Country Dynamics
- 8.3.5.2 Target Disease Prevalence
- 8.3.5.3 Competitive Scenario
- 8.3.5.4 Regulatory Framework
- 8.3.5.5 Reimbursement Scenario
- 8.3.5.6 Italy HLA typing market, by product
- 8.3.5.7 Italy HLA typing market, by application
- 8.3.5.8 Italy HLA typing market, by End-user
- 8.3.5.9 Italy HLA typing market, by technique
- 8.3.6 Spain
- 8.3.6.1 Key Country Dynamics
- 8.3.6.2 Target Disease Prevalence
- 8.3.6.3 Competitive Scenario
- 8.3.6.4 Regulatory Framework
- 8.3.6.5 Reimbursement Scenario
- 8.3.6.6 Spain HLA typing market, by product
- 8.3.6.7 Spain HLA typing market, by application
- 8.3.6.8 Spain HLA typing market, by End-user
- 8.3.6.9 Spain HLA typing market, by technique
- 8.3.7 Denmark
- 8.3.7.1 Key Country Dynamics
- 8.3.7.2 Target Disease Prevalence
- 8.3.7.3 Competitive Scenario
- 8.3.7.4 Regulatory Framework
- 8.3.7.5 Reimbursement Scenario
- 8.3.7.6 Denmark HLA typing market, by product
- 8.3.7.7 Denmark HLA typing market, by application
- 8.3.7.8 Denmark HLA typing market, by End-user
- 8.3.7.9 Denmark HLA typing market, by technique
- 8.3.8 Sweden
- 8.3.8.1 Key Country Dynamics
- 8.3.8.2 Target Disease Prevalence
- 8.3.8.3 Competitive Scenario
- 8.3.8.4 Regulatory Framework
- 8.3.8.5 Reimbursement Scenario
- 8.3.8.6 Sweden HLA typing market, by product
- 8.3.8.7 Sweden HLA typing market, by application
- 8.3.8.8 Sweden HLA typing market, by End-user
- 8.3.8.9 Sweden HLA typing market, by technique
- 8.3.9 Norway
- 8.3.9.1 Key Country Dynamics
- 8.3.9.2 Target Disease Prevalence
- 8.3.9.3 Competitive Scenario
- 8.3.9.4 Regulatory Framework
- 8.3.9.5 Reimbursement Scenario
- 8.3.9.6 Norway HLA typing market, by product
- 8.3.9.7 Norway HLA typing market, by application
- 8.3.9.8 Norway HLA typing market, by End-user
- 8.3.9.9 Norway HLA typing market, by technique
- 8.4 Asia Pacific
- 8.4.1 SWOT Analysis
- 8.4.1.1 Asia Pacific HLA typing market, by product
- 8.4.1.2 Asia Pacific HLA typing market, by application
- 8.4.1.3 Asia Pacific HLA typing market, by End-user
- 8.4.1.4 Asia Pacific HLA typing market, by technique
- 8.4.2 Japan
- 8.4.2.1 Key Country Dynamics
- 8.4.2.2 Target Disease Prevalence
- 8.4.2.3 Competitive Scenario
- 8.4.2.4 Regulatory Framework
- 8.4.2.5 Reimbursement Scenario
- 8.4.2.6 Japan HLA typing market, by product
- 8.4.2.7 Japan HLA typing market, by application
- 8.4.2.8 Japan HLA typing market, by End-user
- 8.4.2.9 Japan HLA typing market, by technique
- 8.4.3 China
- 8.4.3.1 Key Country Dynamics
- 8.4.3.2 Target Disease Prevalence
- 8.4.3.3 Competitive Scenario
- 8.4.3.4 Regulatory Framework
- 8.4.3.5 Reimbursement Scenario
- 8.4.3.6 China HLA typing market, by product
- 8.4.3.7 China HLA typing market, by application
- 8.4.3.8 China HLA typing market, by End-user
- 8.4.3.9 China HLA typing market, by technique
- 8.4.4 India
- 8.4.4.1 Key Country Dynamics
- 8.4.4.2 Target Disease Prevalence
- 8.4.4.3 Competitive Scenario
- 8.4.4.4 Regulatory Framework
- 8.4.4.5 Reimbursement Scenario
- 8.4.4.6 India HLA typing market, by product
- 8.4.4.7 India HLA typing market, by application
- 8.4.4.8 India HLA typing market, by End-user
- 8.4.4.9 India HLA typing market, by technique
- 8.4.5 South Korea
- 8.4.5.1 Key Country Dynamics
- 8.4.5.2 Target Disease Prevalence
- 8.4.5.3 Competitive Scenario
- 8.4.5.4 Regulatory Framework
- 8.4.5.5 Reimbursement Scenario
- 8.4.5.6 South Korea HLA typing market, by product
- 8.4.5.7 South Korea HLA typing market, by application
- 8.4.5.8 South Korea HLA typing market, by End-user
- 8.4.5.9 South Korea HLA typing market, by technique
- 8.4.6 Australia
- 8.3.9.1 Key Country Dynamics
- 8.4.6.2 Target Disease Prevalence
- 8.4.6.3 Competitive Scenario
- 8.4.6.4 Regulatory Framework
- 8.4.6.5 Reimbursement Scenario
- 8.4.6.6 Australia HLA typing market, by product
- 8.4.6.7 Australia HLA typing market, by application
- 8.4.6.8 Australia HLA typing market, by End-user
- 8.4.6.9 Australia HLA typing market, by technique
- 8.4.7 Thailand
- 8.4.7.1 Key Country Dynamics
- 8.4.7.2 Target Disease Prevalence
- 8.4.7.3 Competitive Scenario
- 8.4.7.4 Regulatory Framework
- 8.4.7.5 Reimbursement Scenario
- 8.4.7.6 Thailand HLA typing market, by product
- 8.4.7.7 Thailand HLA typing market, by application
- 8.4.7.8 Thailand HLA typing market, by End-user
- 8.4.7.9 Thailand HLA typing market, by technique
- 8.5 Latin America
- 8.5.1 SWOT Analysis
- 8.5.1.1 Latin America HLA typing market, by product
- 8.5.1.2 Latin America HLA typing market, by application
- 8.5.1.3 Latin America HLA typing market, by End-user
- 8.5.1.4 Latin America HLA typing market, by technique
- 8.5.2 Brazil
- 8.5.2.1 Key Country Dynamics
- 8.5.2.2 Target Disease Prevalence
- 8.5.2.3 Competitive Scenario
- 8.5.2.4 Regulatory Framework
- 8.5.2.5 Reimbursement Scenario
- 8.5.2.6 Brazil HLA typing market, by product
- 8.5.2.7 Brazil HLA typing market, by application
- 8.5.2.8 Brazil HLA typing market, by End-user
- 8.5.2.9 Brazil HLA typing market, by technique
- 8.5.3 Mexico
- 8.5.3.1 Key Country Dynamics
- 8.5.3.2 Target Disease Prevalence
- 8.5.3.3 Competitive Scenario
- 8.5.3.4 Regulatory Framework
- 8.5.3.5 Reimbursement Scenario
- 8.5.3.6 Mexico HLA typing market, by product
- 8.5.3.7 Mexico HLA typing market, by application
- 8.5.3.8 Mexico HLA typing market, by End-user
- 8.5.3.9 Mexico HLA typing market, by technique
- 8.5.4 Argentina
- 8.5.4.1 Key Country Dynamics
- 8.5.4.2 Target Disease Prevalence
- 8.5.4.3 Competitive Scenario
- 8.5.4.4 Regulatory Framework
- 8.5.4.5 Reimbursement Scenario
- 8.5.4.6 Argentina HLA typing market, by product
- 8.5.4.7 Argentina HLA typing market, by application
- 8.5.4.8 Argentina HLA typing market, by End-user
- 8.5.4.9 Argentina HLA typing market, by technique
- 8.6 MEA
- 8.6.1 SWOT Analysis
- 8.6.1.1 MEA HLA typing market, by product
- 8.6.1.2 MEA HLA typing market, by application
- 8.6.1.3 MEA HLA typing market, by End-user
- 8.6.1.4 MEA HLA typing market, by technique
- 8.6.2 South Africa
- 8.6.4.1 Key Country Dynamics
- 8.6.2.2 Target Disease Prevalence
- 8.6.2.3 Competitive Scenario
- 8.6.2.4 Regulatory Framework
- 8.6.2.5 Reimbursement Scenario
- 8.6.2.6 Argentina HLA typing market, by product
- 8.6.2.7 Argentina HLA typing market, by application
- 8.6.2.8 Argentina HLA typing market, by End-user
- 8.6.2.9 Argentina HLA typing market, by technique
- 8.6.3 Saudi Arabia
- 8.6.3.1 Key Country Dynamics
- 8.6.3.2 Target Disease Prevalence
- 8.6.3.3 Competitive Scenario
- 8.6.3.4 Regulatory Framework
- 8.6.3.5 Reimbursement Scenario
- 8.6.3.6 Saudi Arabia HLA typing market, by product
- 8.6.3.7 Saudi Arabia HLA typing market, by application
- 8.6.3.8 Saudi Arabia HLA typing market, by End-user
- 8.6.3.9 Saudi Arabia HLA typing market, by technique
- 8.6.4 UAE
- 8.6.4.1 Key Country Dynamics
- 8.6.4.2 Target Disease Prevalence
- 8.6.4.3 Competitive Scenario
- 8.6.4.4 Regulatory Framework
- 8.6.4.5 Reimbursement Scenario
- 8.6.4.6 UAE HLA typing market, by product
- 8.6.4.7 UAE HLA typing market, by application
- 8.6.4.8 UAE HLA typing market, by End-user
- 8.6.4.9 UAE HLA typing market, by technique
- 8.6.5 Kuwait
- 8.6.5.1 Key Country Dynamics
- 8.6.5.2 Target Disease Prevalence
- 8.6.5.3 Competitive Scenario
- 8.6.5.4 Regulatory Framework
- 8.6.5.5 Reimbursement Scenario
- 8.6.5.6 Kuwait HLA typing market, by product
- 8.6.5.7 Kuwait HLA typing market, by application
- 8.6.5.8 Kuwait HLA typing market, by End-user
- 8.6.5.9 Kuwait HLA typing market, by technique
Chapter 9 Competitive Landscape
- 9.1 Participant's overview
- 9.2 Financial performance
- 9.3 Participant categorization
- 9.3.1 Market leaders
- 9.3.1.1 HLA typing market share analysis, 2022
- 9.3.1.2 Company profiles
- 9.3.1.2.1 Thermo Fisher Scientific Inc.
- 9.3.1.2.2 Bio-Rad Laboratories Inc.
- 9.3.1.2.3 Qiagen N.V.
- 9.3.1.2.4 Omixon Inc.
- 9.3.1.2.5 GenDx
- 9.3.1.2.6 Illumina Inc.
- 9.3.1.2.7 TBG Diagnostics Limited
- 9.3.1.2.8 Dickinson and Company
- 9.3.1.2.9 Takara Bio Inc.
- 9.3.1.2.10 F. Hoffman-La Roche Limited
- 9.3.1.2.11 Pacific Biosciences
- 9.3.2 Strategy mapping
- 9.3.2.1 Expansion
- 9.3.2.2 Acquisition
- 9.3.2.3 Collaborations
- 9.3.2.4 Product/service launch
- 9.3.2.5 Partnerships
- 9.3.2.6 Others